Moderna to Pause Enrollment in Some Clinical Trials as a Result of the COVID-19 Pandemic
Moderna (NASDAQ: MRNA) recently announced that it would join the growing list of drugmakers adjusting their clinical trial activities in light of the COVID-19 pandemic. The biotech company -- which focuses on developing vaccines and treatments using mRNA technology -- will pause enrollment in several studies.
The company will no longer enroll new patients in its phase 1 clinical trial investigating the safety and tolerability of escalating doses of mRNA-3704, an investigational treatment for the rare metabolic disorder methylmalonic acidemia.
Also, the company will pause enrollment in its phase 1 clinical trial for mRNA-3927, a potential treatment for propionic acidemia, which is also a metabolic disorder. Lastly, its phase 1 trial for mRNA-1653 -- a potential vaccine for two respiratory illnesses -- human metapneumovirus and parainfluenza virus 3 -- will also go on hiatus.
Source Fool.com
